Abstract:As our understanding of the complex interactions between the immune system and cancer has progressed, so has the identification of novel targets and ligands that can modulate effective anti-cancer immune responses. While immunotherapy has emerged as a mainstay in cancer therapy, its efficacy has been limited by the potential for off-target toxicity against normal body cells. In this study, we present a nanoparticle-based delivery system that enhances the signaling efficacy of immunomodulatory ligands while concurrently limiting systemic toxicity. We demonstrate that extracellular vesicles (EVs), lipid bilayer enclosed nanoparticles released by cells, can be efficiently engineered to display multiple immunomodulatory ligands on their surface. Display of immunomodulatory ligands such as agonistic CD137 and CD40 antibodies on the EV surface significantly enhanced their therapeutic efficacy over equivalent doses of free ligands by inducing ligand multimerization, efficient receptor crosslinking and the formation of immune synapses. EVs conjugated with a complementary combination of immune stimulatory ligands and immune checkpoint inhibitors were able to shift the tumor immune milieu towards an anti-tumorigenic phenotype in a lung metastatic melanoma allograft and suppress tumor progression to a greater extent than an equivalent dose of free ligands. We also demonstrate the ability of EVs to co-deliver intraluminally loaded TLR agonists which synergize with surface displayed agonistic CD40 antibodies to induce effective anti-tumor responses and tumor regression in a metastatic autochthonous cell-derived model of PDAC. Remarkably, we also observed that EV-associated immunotherapeutics were limited in their biodistribution to the tumor microenvironment, resulting in significantly lower off-target toxicity than treatment with free ligands. In summary, we present an EV-based delivery approach that allows the use of potent cancer immunotherapy combinations to achieve superior anti-tumor responses at significantly lower doses with less side-effects than is possible with conventional administration methods for cancer immunotherapy. Citation Format: Migara Kavishka Jayasinghe, Dawn Liu Xiao Tian, Yock Sin Lay, Chang Yu Lee, Brendon Zhi Jie Yeo, Dong Van Hoang, Rebecca Carissa Prajogo, Boya Peng, Thach Tuan Pham, Minh Thi Nguyet Le. Extracellular Vesicle Surface Display Enhances the Therapeutic Efficacy and Safety Profile of Cancer Immunotherapy [abstract]. In: Proceedings of Frontiers in Cancer Science; 2023 Nov 6-8; Singapore. Philadelphia (PA): AACR; Cancer Res 2024;84(8_Suppl) nr LT08.

Design and Evaluation of Engineered Extracellular Vesicle (EV)-Based Targeting for EGFR-Overexpressing Tumor Cells Using Monobody Display

Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting

Antibody-displaying extracellular vesicles for targeted cancer therapy

An off-the-shelf small extracellular vesicle nanomedicine for tumor targeting therapy

Engineered Extracellular Vesicles with Compound-Induced Cargo Delivery to Solid Tumors

Engineered mesenchymal stem cell-derived extracellular vesicles constitute a versatile platform for targeted drug delivery

Enhancing precision targeting of ovarian cancer tumor cells in vivo through extracellular vesicle engineering

Engineered extracellular vesicles with polypeptide for targeted delivery of doxorubicin against EGFR‐positive tumors

Metabolic tagging of extracellular vesicles and development of enhanced extracellular vesicle based cancer vaccines

Engineered extracellular vesicles: A new approach for targeted therapy of tumors and overcoming drug resistance

Targeted therapy using engineered extracellular vesicles: principles and strategies for membrane modification

Engineered Extracellular Vesicles for Cancer Therapy

Extracellular vesicle surface display of αPD‐L1 and αCD3 antibodies via engineered late domain‐based scaffold to activate T‐cell anti‐tumor immunity

Application of engineered extracellular vesicles for targeted tumor therapy

CD81-guided heterologous EVs present heterogeneous interactions with breast cancer cells

Engineered Extracellular Vesicles as a Targeted Delivery Platform for Precision Therapy

Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery

Assessing the conjugation efficiency of surface-modified extracellular vesicles using single nanovesicle analysis technologies

Abstract LT08: Extracellular Vesicle Surface Display Enhances the Therapeutic Efficacy and Safety Profile of Cancer Immunotherapy

Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles

Targeted EV to Deliver Chemotherapy to Treat Triple-Negative Breast Cancers